In a clinical trial, Paxlovid showed an 89% reduction in the risk of hospitalisation and death.

The company said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatmen...

The approval by the Central Drugs Standard Control Organization (CDSCO) has been granted under the emergency authorization route considerin...

The company said that Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms ...

Pfizer’s Paxlovid contains Nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and Ritonavir, which slows...

Pfizer had last year announced a deal with MPP, a UN-backed body, to issue royalty-free voluntary licences to manufacture generic versions ...

US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immu...

Reliance Retail Ventures announced the acquisition of a majority 89 per cent equity stake in Clovia, an industry leader in the bridge-to-pr...

These include Cipla, Sun Pharma, Laurus Labs, Divi's Laboratories, Glenmark, Emcure, Macleods, SMS Pharmaceuticals, Strides, Torrent, Cadil...

Torrent said that t it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how ...

The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir...

Pfizer has entered into advance purchase agreements with multiple countries. Sources told ET that Pfizer is yet to apply for emergency use ...

Bangladesh's directorate general of drug administration on Thursday granted emergency use authorisation for the oral antiviral drug to trea...

Pfizer's novel antiviral pill showed almost 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent data f...

The company has begun investing $1 billion, at risk, in the manufacture of its potential Covid-19 oral antiviral drug with the goal of maki...

Final results of Paxlovid demonstrated reduction of hospitalisation or death by 89% among high-risk patients treated within three days of s...

The company said the 88% efficacy in patients treated within five days of symptom onset, was an increase from the 85% observed in the inter...